Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial
By
Hubert H. Fernandez
Stuart H. Isaacson
Robert A. Hauser
Pinky Agarwal
William Ondo
Ariane Park
Daniel Kremens
Matthew Leoni
Sridhar Duvvuri
Cari Combs
Erica Koenig
Ih Chang
Gina Pastino
Stacey Tringali
Nicole Golonski
Raymond Sanchez
Linda Harmer
Joey Boiser
Cindy Zadikoff
Zoltan Mari
May 1, 2026
Clinical Scorecard: Tavapadon as a Complementary Therapy for Parkinson's Disease: Findings from the TEMPO-3 Randomized Clinical Study
At a Glance
Category Detail
Condition Parkinson's Disease (PD) Key Mechanisms Dopamine receptor agonism targeting D1/D5 receptors to improve motor control. Target Population Adults aged 40 to 80 years with PD experiencing motor fluctuations. Care Setting Multicenter clinical trial across 14 countries.
Key Highlights
Tavapadon is a novel, selective D1/D5 agonist for PD. Phase 3 TEMPO-3 trial evaluated tavapadon as adjunctive therapy to levodopa. Participants experienced significant improvement in on-time without troublesome dyskinesia. Tavapadon demonstrated an acceptable safety and tolerability profile. The trial followed rigorous ethical and reporting guidelines. Guideline-Based Recommendations
Diagnosis
Diagnosis of PD consistent with UK Parkinson Disease Brain Bank criteria. Management
Tavapadon titrated to a maximum of 15 mg once daily as adjunctive therapy to stable levodopa. Monitoring & Follow-up
Monitor for adverse events and efficacy through Hauser diary assessments. Risks
Potential for adverse events including impulse control disorders and hallucinations. Patient & Prescribing Data
Adults aged 40-80 with a modified Hoehn & Yahr score of 2-3.
Tavapadon may reduce motor fluctuations and improve quality of life.
Clinical Best Practices
Ensure stable levodopa dosing before initiating tavapadon. Conduct regular assessments of motor function and adverse events. Educate patients on the potential risks associated with dopamine agonists. Related Resources & Content
